The case of a previously healthy HIV seronegative woman with disseminated Mycobacterium tuberculosis infection and markedly reduced interferon c production is reported here. Complete healing of her disseminated lesions was seen only after addition of subcutaneous interferon c to her tuberculosis treatment.
I
nfections with intracellular bacteria such as mycobacteria are an important cause of human morbidity and mortality worldwide. Immunological protection against such organisms depends heavily on cell-mediated immunity, with the major effector being the interferon (IFN) c activated macrophage. 1 The importance of IFNc pathways in host defence against intracellular bacteria was clarified by experimental studies on knockout mice. More recently, the identification and characterisation of humans with mutations in IFNc receptor proteins, interleukin (IL)12 receptor b1 or IL12 p40 has confirmed the importance of these pathways in human-host defence. Defects in the IFNc/IL12 axis are well known to predispose individuals to infection with non-tuberculous mycobacteria or Salmonella species. 2 To date, IFNc deficiency in humans has not been described, despite the identification of numerous IFNc receptor mutations in humans. The IFNc mouse-knockout model indicated that IFNc is not required for normal growth and development. However, these mice do not develop protective immunity after experimental infection with Mycobacterium bovis, Bacillus calmette guerin or M tuberculosis Erdman strain. 3 4 Further, IFNc knockout mice experimentally infected with certain M avium strains develop higher tissue levels of bacteria than wild-type mice and they do not develop protective immunity to some attenuated strains of Salmonella typhimurium. 5 We report on a previously healthy HIV seronegative woman with disseminated M tuberculosis infection due to a defect in IFNc production.
CASE REPORT
A 56-year-old white Caucasian woman presented with fever and right-sided chest pain, and was found to have a right pleural effusion confirmed on chest radiography ( fig 1A) . M tuberculosis (sensitive to standard and second-line tuberculosis drugs) was isolated from pleural biopsy material and standard quadruple tuberculosis treatment was started. Four months later, while taking standard tuberculosis treatment with documented compliance, she developed lower back pain and several discharging sinuses in her left forearm and palm ( fig 1B) . At this juncture there was minimal improvement in her right pleural fluid collection. A computed tomography scan of the abdomen showed a non-functioning left kidney with cystic changes (fig 1C) , a magnetic resonance imaging vertebral scan showed vertebral body collapse with loss of intervertebral disc height (fig 1D) , and a magnetic resonance imaging hand/ forearm scan showed hyperdense material in the soft tissues of the hand (fig 1E) . A left nephrectomy was undertaken and macroscopically the appearance was of renal tuberculosis. Microscopically, poorly formed granuloma with several acid fast bacilli were noted. Smears taken at this time were acid fast bacilli positive and M tuberculosis (sensitive to the drugs the patient was taking at the time) was cultured. M tuberculosis was also cultured from pleural fluid and from an early morning urine specimen. There was a strong family history of tuberculosis. Her father had died of tuberculosis at age 40 years despite treatment, her paternal uncle had tuberculosis and her paternal grandmother had died of tuberculosis at age 37 years. She was HIV negative and basic immunological tests showed: normal immunoglobulins, specific antibodies and lymphocyte subsets, with marginally reduced lymphocyte proliferation to OKT3. Cytokine quantification after whole blood stimulation showed markedly reduced IFNc production (both before treatment and after clinical resolution; fig 2) . IFNc and IL12 receptor functions and TNFa and IL12 levels were normal (fig 2) , with no anti-IFNc antibodies detected (data not shown) 6 . As her clinical condition was deteriorating despite administration of standard tuberculosis chemotherapy for 8 months with good compliance for a fully sensitive organism, subcutaneous IFNc three times a week (50 mg for 2 weeks, 75 mg for 16 weeks followed by 50 mg for 32 weeks) was added to her tuberculosis treatment. The addition of IFNc produced rapid improvement in her progressively worsening condition. IFNc and tuberculosis treatments were continued for 12 months, followed by tuberculosis drugs alone for a further 3 months. No major adverse effects of IFNc treatment were seen. There was complete healing (both clinical and radiological) of kidney, skin and bone lesions, and the pleural shadowing was largely resolved. In addition, the patient's weight increased by 5 kg, inflammatory markers which had previously been markedly raised (C reactive protein .100, erythrocyte sedimentation rate .100) returned to normal, and she was able to resume her job that she had given up at the time her disease was becoming progressively worse. At follow-up, 9 months after stopping tuberculosis treatment, she remains well.
DISCUSSION
Our patient, a previously healthy HIV seronegative woman with disseminated M tuberculosis infection, was found to have markedly reduced IFNc production. The addition of subcutaneous IFNc to her tuberculosis treatment led to complete healing of the disseminated lesions.
The importance of IFNc pathways in host defence has been demonstrated in mice with targeted disruptions of the IFNc, IFNcR1 or IFNcR2 genes. Although similar problems with immunity to mycobacteria are seen in individuals with defects in IFNc receptors, to our knowledge, M tuberculosis due to IFNc deficiency has not been reported previously. /well, Statens Institute Copenhagen, Denmark) and lipopolysaccharide (LPS) (1 mg/ml, List Biochemicals Epson, UK). Supernatants were taken at 12 h (TNFa, IL12) and 48 h (IFNc). Cytokines were measured using standard ELISA according to the manufacturer's recommendations (IFNc, TNFa: CLB; IL12: R&D Systems). One representative out of two experiments is shown. In-house reference ranges (mean (SD) pg/ml) for IFNc production are: medium, 5.8 (16); IL12, 24 (62); PHA, 6628 (4209); PHA+IL12, 26 166 (14 657); BCG, 151 (225).
